Sage Submissions Releases New eCTD Template Support for EMEA Module 1
Sage Submissions
has released Sage Templates, version 1.1.3. Sage Templates OneVoice feature enables documents to be created across the organization and by outside authors with a consistent look-and-feel. This enables the creation of consistent formatted submissions instead of several formats and document navigation structures.
Extensive customer input was gathered to enhance the design of Sage Templates and to extend the number of templates available to authors of submission documents with Version 1.1.3. Sage Templates are available as a complete set for all stages of submissions in North American and Europe and includes:
· US eCTD
· EU eCTD
· IND
· CTA-IMPD templates for Europe and
· CTA-A templates for Canada
Templates are also available as subsets to provide a low cost acquisition point for companies that prepare Drug Master Files, CROs that conduct nonclinical or clinical studies, or companies that submit only IND, CTA-IMPD or CTA-A submissions.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
